C. Black

发表

Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Longitudinal follow‐up of a novel classification system for irritable bowel syndrome: natural history and prognostic value

R. West, A. Ford, L. Houghton, 2021, Alimentary pharmacology & therapeutics.

Prognosis of patients with Rome IV‐defined versus physician‐diagnosed irritable bowel syndrome: Longitudinal follow‐up study

A. Ford, Vivek C Goodoory, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Natural History and Disease Impact of Rome IV versus Rome III Irritable Bowel Syndrome: A Longitudinal Follow-up Study.

A. Ford, L. Houghton, Vivek C Goodoory, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.

E. Savarino, A. Ford, L. Houghton, 2020, The American journal of gastroenterology.

Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care

A. Ford, C. Black, D. Gracie, 2020, Gut.

Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow‐up study

Shujing Jane Lim, A. Ford, A. Scarsbrook, 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation

A. Ford, L. Houghton, C. Black, 2021, Alimentary pharmacology & therapeutics.

Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis

L. Eusebi, A. Ford, C. Black, 2019, BMJ.

British Society of Gastroenterology guidelines on the management of functional dyspepsia

A. Ford, L. Houghton, M. Corsetti, 2022, Gut.

Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities

A. Ford, L. Houghton, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation.

A. Ford, C. Black, N. Burr, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis

C. Black, H. Tsai, 2016, Expert review of pharmacoeconomics & outcomes research.

Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.

P. Moayyedi, M. Camilleri, Yuhong Yuan, 2019, The lancet. Gastroenterology & hepatology.

Global burden of irritable bowel syndrome: trends, predictions and risk factors

A. Ford, C. Black, 2020, Nature Reviews Gastroenterology & Hepatology.

Systematic review and meta‐analysis: efficacy of peppermint oil in irritable bowel syndrome

P. Moayyedi, A. Ford, G. Ianiro, 2022, Alimentary pharmacology & therapeutics.

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis

A. Ford, C. Black, D. Gracie, 2022, Gut.

Diet and irritable bowel syndrome: an update from a UK consensus meeting

D. Sanders, C. Black, I. Aziz, 2022, BMC Medicine.

Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply

P. Moayyedi, A. Ford, G. Ianiro, 2022, Alimentary pharmacology & therapeutics.

This is a repository copy of Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

L. Eusebi, A. Ford, G. Ianiro, 2020 .

Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value‐based care for a high‐prevalence, low‐cost condition. Authors' reply

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Editorial: subgroups in irritable bowel syndrome—more than just diarrhoea and constipation?

A. Ford, C. Black, 2017, Alimentary pharmacology & therapeutics.

Peppermint Oil in Irritable Bowel Syndrome.

P. Moayyedi, A. Ford, C. Black, 2020, Gastroenterology.

Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.

P. Moayyedi, A. Ford, L. Houghton, 2018, Gastroenterology.

Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials.

E. Savarino, A. Ford, C. Black, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives.

A. Ford, C. Black, 2020, The American journal of gastroenterology.

Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis

A. Ford, C. Black, D. Gracie, 2021, Gut.

Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta‐analysis

E. Savarino, A. Ford, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Comparison of acid‐lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta‐Analysis

E. Savarino, A. Ford, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria.

E. Savarino, A. Ford, C. Black, 2020, Alimentary pharmacology & therapeutics.

Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.

E. Savarino, A. Ford, C. Black, 2020, The lancet. Gastroenterology & hepatology.

Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.

M. Camilleri, A. Ford, E. Quigley, 2019, The lancet. Gastroenterology & hepatology.

Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management

A. Ford, C. Black, 2018, The Medical journal of Australia.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

A. Ford, A. Farmer, L. Houghton, 2021, Gut.

Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.

E. Savarino, A. Ford, C. Black, 2021, The lancet. Gastroenterology & hepatology.

Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2020, Journal of Crohn's & colitis.

Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis

A. Ford, C. Black, H. Staudacher, 2021, Gut.

Systematic review with meta‐analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

A. Gasbarrini, L. Eusebi, A. Ford, 2019, Alimentary pharmacology & therapeutics.

Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis

P. Moayyedi, M. Camilleri, A. Ford, 2019, Gut.

Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms

P. Moayyedi, E. Savarino, A. Ford, 2020, Alimentary pharmacology & therapeutics.

Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2021, Journal of Crohn's & colitis.

Review article: Diagnosis and investigation of irritable bowel syndrome

C. Black, C. Black, 2021, Alimentary pharmacology & therapeutics.

R. West, A. Ford, L. Houghton, 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Rational investigations in irritable bowel syndrome

A. Ford, C. Black, 2019, Frontline Gastroenterology.

Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

C. Black, C. Selinger, A. Ford, 2022, Alimentary pharmacology & therapeutics.

Functional gastrointestinal disorders: advances in understanding and management

D. Drossman, A. Ford, N. Talley, 2020, The Lancet.

Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

E. Savarino, A. Ford, C. Black, 2021 .

Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis.

A. Ford, C. Black, D. Gracie, 2023, Inflammatory bowel diseases.

Systematic review and network meta‐analysis: efficacy of drugs for functional dyspepsia

P. Moayyedi, Yuhong Yuan, A. Ford, 2020, Alimentary pharmacology & therapeutics.

Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply

C. Ng, C. Black, E. Guthrie, 2023, Alimentary pharmacology & therapeutics.

Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis.

A. Ford, C. Black, N. Mohammed, 2020, The lancet. Gastroenterology & hepatology.

Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis

P. Moayyedi, A. Ford, L. Houghton, 2020, Gut.

Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-up Study.

E. Savarino, A. Ford, L. Houghton, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome with Constipation or Diarrhea: Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Best management of irritable bowel syndrome

A. Ford, C. Black, 2020, Frontline Gastroenterology.

Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea.

A. Ford, C. Black, 2020, The American journal of gastroenterology.

Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea.

A. Ford, L. Houghton, C. Black, 2020, The American journal of gastroenterology.

Impact of Rome IV irritable bowel syndrome on work and activities of daily living

A. Ford, C. Ng, C. Black, 2022, Alimentary pharmacology & therapeutics.

Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome

A. Ford, L. Houghton, A. Mikocka-Walus, 2021, The American journal of gastroenterology.

A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.

R. West, A. Ford, L. Houghton, 2020, The American journal of gastroenterology.

Factors associated with lower disease‐specific and generic health‐related quality of life in Rome IV irritable bowel syndrome

C. Ng, C. Black, E. Guthrie, 2022, Alimentary pharmacology & therapeutics.

Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.

A. Ford, L. Houghton, C. Black, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.

A. Ford, C. Black, E. Guthrie, 2022, The American journal of gastroenterology.

Insights into the evaluation and management of dyspepsia: recent developments and new guidelines

A. Ford, L. Houghton, C. Black, 2018, Therapeutic advances in gastroenterology.

A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care

C. Black, S. Mahadeva, A. Ford, 2023, Alimentary pharmacology & therapeutics.

Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders

A. Ford, L. Houghton, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome

C. Ng, C. Black, A. Ford, 2023, Alimentary pharmacology & therapeutics.

Editorial: co‐morbid gastrointestinal conditions are an important consideration in IBS management—authors' reply

A. Ford, C. Black, 2021, Alimentary pharmacology & therapeutics.

Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply

A. Ford, C. Black, B. Barberio, 2021, Alimentary pharmacology & therapeutics.

Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management

S. Teasdale, A. Mikocka-Walus, C. Black, 2023, Nature Reviews Gastroenterology & Hepatology.

A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care.

C. Black, D. Gracie, O. Craig, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome

A. Ford, C. Ng, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply

C. Ng, C. Black, E. Guthrie, 2023, Alimentary Pharmacology and Therapeutics.

Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply

C. Ng, C. Black, A. Ford, 2023, Alimentary pharmacology & therapeutics.

Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis.

C. Black, D. Gracie, B. Barberio, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

P. Whorwell, R. Spiller, A. Forbes, 2000, Gut.

Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome.

A. Ford, C. Black, 2022, Gastroenterology.

The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study

P. Whorwell, L. Houghton, Robert West, 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Irritable bowel syndrome: a spotlight on future research needs.

A. Ford, C. Black, 2021, The lancet. Gastroenterology & hepatology.

AJG-20-4059 1485..1494

A. Ford, L. Houghton, C. Black, 2022 .

How effective are antibiotics for the treatment of irritable bowel syndrome?

A. Ford, C. Black, 2020, Expert opinion on pharmacotherapy.

Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis

E. Savarino, C. Black, B. Barberio, 2023, Gut.

Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.

C. Black, K. Fairbrass, D. Gracie, 2023, Alimentary pharmacology & therapeutics.

Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

E. Savarino, C. Black, B. Barberio, 2020, Journal of Crohn's & colitis.

Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome—authors' reply

C. Ng, C. Black, A. Ford, 2023, Alimentary pharmacology & therapeutics.

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.

A. Ford, C. Black, A. Tuteja, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.